Northern Trust’s Plus Therapeutics PSTV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$47.7K Hold
11,732
﹤0.01% 4252
2025
Q4
$150K Buy
11,732
+1,112
+10% +$16.8K ﹤0.01% 4061
2025
Q3
$182K Buy
+10,620
New +$130K ﹤0.01% 4010
2023
Q2
Sell
-154
Closed -$16.7K 4580
2023
Q1
$16.7K Buy
154
+68
+79% +$9.15K ﹤0.01% 4477
2022
Q4
$10.2K Hold
86
﹤0.01% 4572
2022
Q3
$14K Hold
86
﹤0.01% 4604
2022
Q2
$17K Hold
86
﹤0.01% 4645
2022
Q1
$32K Hold
86
﹤0.01% 4609
2021
Q4
$34K Hold
86
﹤0.01% 4650
2021
Q3
$61K Sell
86
-22
-20% -$16.8K ﹤0.01% 4497
2021
Q2
$104K Buy
+108
New +$97.6K ﹤0.01% 4356
2018
Q2
Hold
0
-$16K 4324
2018
Q1
Hold
0
4181
2017
Q4
Hold
0
4167
2017
Q3
Hold
0
4158
2017
Q2
Hold
0
4055
2017
Q1
Hold
0
3980
2016
Q4
Hold
0
4081
2016
Q3
Hold
0
4054
2016
Q2
Hold
0
4056
2016
Q1
Hold
0
4094
2015
Q4
Hold
0
4151
2015
Q3
Hold
0
4096
2015
Q2
Hold
0
3601
2015
Q1
Hold
0
3430
2014
Q4
Hold
0
3654
2014
Q3
Hold
0
3576
2014
Q2
Hold
0
3192
2014
Q1
Hold
0
3109
2013
Q4
Hold
0
3096
2013
Q3
Hold
0
3094
2013
Q2
Hold
0
3004

Other funds holding PSTV

Northern Trust's PSTV Position: Q1 2026 in Review

Northern Trust held its Plus Therapeutics (PSTV) position steady in Q1 2026 at 11,732 shares worth $47.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4252.

Northern Trust first reported a position in PSTV in Q2 2021 and has held it in 11 quarters since. The position peaked at $182K in Q3 2025. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

  • Northern Trust held 11,732 shares of Plus Therapeutics worth $47.7K as of Q1 2026.
  • Northern Trust left its Plus Therapeutics share count unchanged in Q1 2026.
  • Plus Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4252 holding.
  • Northern Trust first reported a position in Plus Therapeutics in Q2 2021 and has held it in 11 quarters since.
  • Northern Trust's Plus Therapeutics position peaked at $182K in Q3 2025.
  • 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.